Rochester, MN - Results of a registry study out of the Mayo Clinic suggest that abciximab does not increase the risk of bleeding in patients with chronic renal insufficiency (CRI) undergoing PCI. The ...

The new analysis, published in the April 13, 2005 issue of the Journal of the American Medical Association, included 11 published randomized trials of abciximab vs controls in a total of 27 115 STEMI ...

Review the side-effects of Abciximab as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Intracoronary administration of abciximab during primary PCI in diabetic patients with STEMI may enhance procedural efficacy and improve clinical outcomes, a pooled patient-level analysis indicates.

Early administration of abciximab has been shown to improve clinical outcomes in patients with acute myocardial infarction (MI). The effect of this agent on angiographic factors and left ventricular ...

Whether the glycoprotein IIb/IIIa inhibitor abciximab is beneficial in patients undergoing elective percutaneous coronary intervention after pretreatment with clopidogrel is unknown. The incidence of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. CHICAGO – The addition of abciximab to clopidogrel ...

Results of the AIDA STEMI MRI Sub-Study Presented at TCT 2012 MIAMI, FL – A study confirmed no differences in various measures of heart damage, according to cardiac magnetic resonance (MRI) imaging, ...

Learn everything you need to know about Abciximab-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

In the setting of percutaneous coronary revascularization, agents in the class known as platelet glycoprotein IIb/IIIa inhibitors have significantly reduced the incidence of death or nonfatal ...

Eptifibatide as an adjunct to percutaneous coronary intervention was equally efficacious to abciximab regarding ST segment resolution in patients treated with percutaneous coronary intervention, study ...

Results of the ISAR-REACT 4 study have shown that combined therapy of abciximab and unfractionated heparin is not associated with a lower 30-day rate of death, large recurrent myocardial infarction, ...